H. Dada

Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma

Y. Kusne, J., M., 2021 .

Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma

V. Master, O. Kucuk, M. Bilen, 2022, The oncologist.

Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer

L. Bucheit, P. Kasi, J. Starr, 2022, Journal for ImmunoTherapy of Cancer.

Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.

V. Papadimitrakopoulou, M. Villalona-Calero, J. Odegaard, 2021, Clinical lung cancer.

Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival

M. Borad, T. Bekaii-Saab, H. Kosiorek, 2022, Frontiers in Oncology.

Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.

D. Gandara, A. Bryce, P. Barata, 2021 .

Circulating tumor DNA (ctDNA) based testing and actionable findings in patients with advanced and metastatic pancreatic adenocarcinoma.

M. Borad, T. Bekaii-Saab, P. Kasi, 2021, The oncologist.